10x Genomics, Inc. (NASDAQ:TXG – Get Rating) has been assigned an average recommendation of "Hold" from the nine ratings firms that are covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $52.86.

A number of research analysts recently issued reports on TXG shares. The Goldman Sachs Group downgraded 10x Genomics from a "neutral" rating to a "sell" rating and dropped their price target for the stock from $55.00 to $35.00 in a research note on Thursday, August 18th. Canaccord Genuity Group started coverage on 10x Genomics in a research note on Monday, July 25th. They set a "buy" rating on the stock. Canaccord Genuity Group initiated coverage on 10x Genomics in a research note on Monday, July 25th. They set a "buy" rating and a $55.00 price target on the stock. Morgan Stanley lowered their target price on 10x Genomics from $100.00 to $70.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 10th. Finally, Cowen lifted their target price on 10x Genomics to $55.00 in a research note on Monday, August 15th.

Insider Buying and Selling

In related news, CEO Serge Saxonov sold 2,715 shares of 10x Genomics stock in a transaction on Tuesday, August 23rd. The stock was sold at an average price of $35.19, for a total transaction of $95,540.85. Following the completion of the transaction, the chief executive officer now directly owns 966,102 shares of the company's stock, valued at $33,997,129.38. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, insider Benjamin J. Hindson sold 1,292 shares of the business's stock in a transaction on Tuesday, August 23rd. The stock was sold at an average price of $35.19, for a total value of $45,465.48. Following the completion of the transaction, the insider now directly owns 186,246 shares of the company's stock, valued at $6,553,996.74. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Serge Saxonov sold 2,715 shares of the business's stock in a transaction on Tuesday, August 23rd. The stock was sold at an average price of $35.19, for a total value of $95,540.85. Following the completion of the transaction, the chief executive officer now directly owns 966,102 shares of the company's stock, valued at $33,997,129.38. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 4,994 shares of company stock valued at $175,739. 11.08% of the stock is owned by insiders.

Institutional Trading of 10x Genomics

10x Genomics Stock Performance

TXG opened at $29.31 on Wednesday. 10x Genomics has a one year low of $28.21 and a one year high of $187.85. The company has a market cap of $3.31 billion, a P/E ratio of -23.26 and a beta of 1.70. The business's 50-day simple moving average is $36.71 and its 200-day simple moving average is $47.70.

10x Genomics (NASDAQ:TXG – Get Rating) last released its quarterly earnings data on Monday, August 8th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.17). The business had revenue of $114.61 million during the quarter, compared to analysts' expectations of $115.89 million. 10x Genomics had a negative net margin of 28.62% and a negative return on equity of 17.77%. The company's revenue was down 1.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.10) EPS. As a group, analysts predict that 10x Genomics will post -1.73 earnings per share for the current fiscal year.

10x Genomics Company Profile

(Get Rating)

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.

Featured Stories

• Get a free copy of the StockNews.com research report on 10x Genomics (TXG)
• Defensive Stocks For A Volatile Market
• SunPower Is Ready To Power Up Triple-Digit Earnings Gains
• Will UPS Be Next to Deliver a Warning?
• Is This the Darkest Before the Dawn for Gap Stock?
• Build A Better Tech Portfolio With Jabil Inc.

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.